CYP7B1 and diabetes mellitus: However, recent studies have proven otherwise as intracellular insulin paucity (characteristic of both type 1 and 2) is what leads to low levels of CYP7B1 and the accumulation of toxic cholesterol metabolites, explaining the existence of MASLD progression with both types of diabetes.